Loading clinical trials...
Loading clinical trials...
Retinal Biomarkers in Parkinson´s Disease: Retinal Oximetry, Pattern Electroretinography (PERG), Visual Evoked Potentials (VEP) and Optical Coherence Tomography (OCT)
The goal of this observational study is to determine whether oxygen content of the retinal vessels of the eye may serve as a biomarker in Parkinson´s disease. The main questions it aims to answer are: 1. Is retinal vessel oxyhemoglobin saturation and vessel width altered in people with Parkinson´s disease? 2. Is the thickness of the retinal nerve fiber layer altered in people with Parkinson´s disease? 3. Is the response of ganglion cells of the inner retina and the visual cortex altered in people with Parkinson´s disease? The study procedure is threefold. The participants will: A. Sit in front of a screen and focus on a red dot of its middle. A simple recording electrodes are applied on the cornea, forehead and scalp for the electrophysiological measurements. Prior to this procedure a topical anesthetic gel is applied to numb the eye to prevent discomfort from placement of the corneal electrodes. B. Undergo general eye examination and optical coherence tomography (OCT) to measure the retinal tissue thickness. Prior to eye examination,eye drops are applied into the eyes to enlarge the pupils C. Sit in front of a fundus camera for obtaining images of the retinal vessels to measure oxygen saturation and the vessel width Researchers will compare the obtained measurements with age- and gender matching of healthy controls.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
Yes
Ophthalmic Outpatient Department Landspitali UH
Reykjavik, Iceland
Start Date
March 10, 2023
Primary Completion Date
December 31, 2026
Completion Date
December 31, 2026
Last Updated
April 15, 2025
60
ESTIMATED participants
Lead Sponsor
Landspitali University Hospital
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06113640